Parkinson's Disease Forecast and Market Analysis to 2035 - Market is Dominated by Generics

Dublin, May 30, 2017 -- Research and Markets has announced the addition of the "Parkinson's Disease Forecast and Market Analysis to 2035" report to their offering.

Sizable pipeline characterized by both high growth and attrition

Parkinson's disease is a chronic and progressive neurodegenerative disorder characterized by tremors, rigidity, bradykinesia (slowness of movement), and postural instability. Patients also experience significant non-motor symptoms including changes in cognition and mood, sleep disturbances, and autonomic dysfunction. The condition is caused by the degeneration of dopamine-producing cells of the substantia nigra. Parkinson's disease is incurable, but non-fatal, resulting in poor quality of life and increasing disability as the disease progresses. Studies classify Parkinson's disease as the second most common neurologic disease following Alzheimer's disease, and it is expected to cause an increasing social and economic burden as populations age.
Recent events and opinion

Parkinson's disease is predominantly treated with longstanding and mature therapies such as levodopa and the dopamine agonists, pramipexole and ropinirole. The market is therefore dominated by generics, with Teva's Azilect (rasagiline) being the last lucrative drug indicated for all Parkinson's disease patients.

Drug developers have responded by introducing new treatment options with clearly defined positions in the market, typically as an option for reducing motor fluctuations alongside levodopa therapy.

The Parkinson's disease pipeline is characterized by a high level of both growth and attrition. The vast majority of Parkinson's disease pipeline candidates are in the preclinical stages of development, however, many programs fail to progress into later stages.

Future clinical trials should aim to target a defined patient population. Clinical trials face difficulties including a high placebo response and poor recruitment of patients. The long duration and slow progressive course of the disease are key factors resulting in clinical trials requiring an extensive amount of resources.

Key Topics Covered:

1. FORECAST: PARKINSON'S DISEASE
Executive Summary
Market Overview and Trends
Market Definition and Methodology
Azilect (rasagiline)
CVT-301
Duopa (levodopa/carbidopa)
Neupro (rotigotine)
Nouriast (istradefylline)
Rytary (carbidopa/levodopa)
Stalevo (carbidopa/levodopa/entacapone)
tozadenant
Xadago (safinamide)
Primary Research Methodology

2. TREATMENT: PARKINSON'S DISEASE
Primary Research Methodology
Disease Definition and Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Unmet Needs in Parkinson's Disease

3. EPIDEMIOLOGY: PARKINSON'S DISEASE
Executive Summary
Disease Background
Sources and Methodology
Forecast
Epidemiologist Insight
Strengths and Limitations

4. MARKETED DRUGS: PARKINSON'S DISEASE
Executive Summary
Product Overview
Product profile: Apokyn
Product profile: Azilect
Product profile: Duopa
Product profile: Mirapex ER
Product profile: Neupro
Product profile: Nouriast
Product profile: Ongentys
Product profile: Rytary
Product profile: Stalevo
Product profile: Xadago

5. PIPELINE: PARKINSON'S DISEASE
Executive Summary
Clinical Pipeline Overview
Product profile (late stage): APL-130277
Product profile (late stage): CVT-301
Product profile (late stage): ND0612
Product profile (late stage): Nurelin
Product profile (late stage): tozadenant

6. APPENDIX

For more information about this report visit http://www.researchandmarkets.com/research/b86ww8/parkinsons

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Central Nervous System Drugs